Aurora CO 神经母细胞瘤临床试验
9项针对 神经母细胞瘤的研究正在 Aurora及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
招募中
- Children's Hospital Colorado, Aurora
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
招募中3 期
- Children's Hospital Colorado, Aurora
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
招募中3 期
- Children's Hospital Colorado, Aurora
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Children's Hospital Colorado, Aurora
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
招募中2 期
- Children's Hospital Colorado, Aurora
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
招募中1/2 期
- Children's Hospital Colorado, Aurora
Neuroblastoma Biology Study
招募中观察性研究
- Children Hospital of Colorado, Aurora
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
招募中2 期
- Children's Hospital of Colorado, Aurora
其他城市的 神经母细胞瘤试验
- Boston, MA13 项研究
- New York City, NY12 项研究
- Washington, DC11 项研究
- Dallas, TX10 项研究
- Cincinnati, OH9 项研究
- St. Louis, MO9 项研究
- Memphis, TN9 项研究
- Philadelphia, PA9 项研究
- Hartford, CT8 项研究
- Birmingham, AL8 项研究
- Harrisburg, PA8 项研究
- Minneapolis, MN8 项研究
Aurora的其他研究
- 癌症(所有类型)34 项研究
- 结直肠癌33 项研究
- 非小细胞肺癌31 项研究
- 乳腺癌30 项研究
- 1型糖尿病26 项研究
- 转移性癌症24 项研究
- 卵巢癌23 项研究
- 肥胖症20 项研究
- 肺癌19 项研究
- 黑色素瘤18 项研究
- 心力衰竭17 项研究
- 前列腺癌17 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年11月15日。每项研究自行设定入选标准,由研究团队决定谁能参与。